Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Roche (RHHBY - Analyst Report) recently announced that the US Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of patients suffering from HER2-positive metastatic breast cancer (mBC).

These patients were previously treated with Herceptin (trastuzumab) and taxane chemotherapy.

The approval was based on positive results from a phase III study (EMILIA: N=991). The study compared Kadcyla (trastuzumab emtansine) to GlaxoSmithKline's (GSK - Analyst Report) Tykerb (lapatinib) along with Roche’s Xeloda (capecitabine) in these patients.  

Roche has partnered with ImmunoGen, Inc. (IMGN - Snapshot Report) for Kadcyla. We note that Roche filed a New Drug Application (NDA) for Kadcyla in Jan 2013 after being granted a priority review in the US in Nov 2012.

In Aug 2012, Roche had filed a Biologics License Application (BLA) for Kadcyla for the treatment of HER2-positive unresectable locally advanced or metastatic breast cancer patients.

Roche also submitted a marketing authorization application for Kadcyla to the European Medicines Agency (EMA) for use in treatment-experienced HER2-positive metastatic breast cancer patients. The application is currently under review.

Meanwhile, in Dec 2012, the European Union’s Committee for Medicinal Products for Human Use (CHMP) gave a positive recommendation for Perjeta (pertuzumab) plus Herceptin (trastuzumab) and docetaxel to treat patients with HER2-positive metastatic or locally recurrent unresectable breast cancer (mBC). 

The approval of Kadcyla will strengthen Roche's HER2 franchise. Roche expects Perjeta, Kadcyla and Actemra to positively impact results in 2013.

Roche currently carries a Zacks Rank #4 (Sell). Another large-cap pharma stock, Bayer (BAYRY - Analyst Report), currently looks attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%